SBIR/STTR Research Award

A Disease-Modifying Protein Therapeutic for the Treatment of COPD

Award identifier a250587776c79731094b5c4c547b12735d9a3fd147362d52cd1a02448720eb51Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$391,023

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VERRA THERAPEUTICS LLC
Proposal award date
2019-09-15
Contract end date
2020-08-31
UEI
WTKNN246ZR43
Solicitation number
PA18-574
Topic code
NHLBI

Research abstract

Project Summary Abstract COPD is projected to become the third most common cause of death worldwideand we currently lack any medical therapies that significantly alter the course of this diseaseOur recent work identifies ADAMa disintegin and metalloproteinase domainas the first proteinase that promotes the three key COPD pulmonary pathologiesemphysemasmall airway fibrosisand airway mucus cell metaplasiain cigarette smoke exposed miceMoreoverADAMexpression is robustly increased in lung epithelial cells and macrophages in the lungs of COPD patientseven in early stage diseaseAdditionallyAdammediates its activitiesin partby increasing lung inflammationdegrading lung elastinand shedding epidermal growth factor receptorEGFRand vascular endothelial growth factor receptorVEGFRto reduce the survival of alveolar septal cellsand increase the number of activated small airway myofibroblastsWe have developed a protein therapeutic based on a domain of ADAMthat specifically targets this enzymeandapos s activity to reduce shedding of a number of substrates for ADAMWe have promising results using this protein in mice acutely exposed to smokeIn Aimwe will establish the pharmacokineticsmaximum tolerated dose and dosing regimen for use in the efficacy studyAimwill focus on performing a proof of concept six month cigarette smoke exposure experiment that will serve to demonstrate satisfactory efficacy of our inhibitorSuccessful completion of the aims will advance this protein therapeutic towards the clinic as the first disease modifying therapy for COPDwith potential to slow the progression of key COPD phenotypes associated with lung function impairmentmorbidity and mortality Narrative Overmillion people have chronic obstructive pulmonary diseaseCOPDand it is projected to become the third most common cause of death word wide byWe have developed a potentially disease modifying therapeutic agent to treat COPDIt is expected to reduce inflammationsmall airway fibrosis and mucus cell metaplasia in a safe and effective manner

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2019–2023). Reported award amounts total $2,390,996. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.